April 13, 2023 – FDA Accepts sBLA for Pembrolizumab/Chemo in Gastric or GEJ Adenocarcinoma

The FDA has accepted a supplemental biologics license application for pembrolizumab (Keytruda) in combination with chemotherapy as a first-line treatment for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, according to a press release from Merck.¹